Memantine, a low-trapping NMDAR antagonist, is approved in the United States and Europe for the treatment of moderate-to-severe Alzheimer's disease,[100] and has now received a limited recommendation by the UK's National Institute for Health and Care Excellence for patients who fail other treatment options.[101]